6OP Stock Overview
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
OSE Immunotherapeutics SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €5.30 |
52 Week High | €6.50 |
52 Week Low | €2.70 |
Beta | 0.78 |
1 Month Change | 12.77% |
3 Month Change | 43.24% |
1 Year Change | 17.78% |
3 Year Change | -54.47% |
5 Year Change | 32.83% |
Change since IPO | -46.84% |
Recent News & Updates
Recent updates
Shareholder Returns
6OP | DE Biotechs | DE Market | |
---|---|---|---|
7D | 14.5% | -5.1% | -2.0% |
1Y | 17.8% | -21.1% | -0.3% |
Return vs Industry: 6OP exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 6OP exceeded the German Market which returned -0.3% over the past year.
Price Volatility
6OP volatility | |
---|---|
6OP Average Weekly Movement | 11.4% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6OP's share price has been volatile over the past 3 months.
Volatility Over Time: 6OP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 62 | Nicolas Poirier | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
6OP fundamental statistics | |
---|---|
Market cap | €128.77m |
Earnings (TTM) | -€23.00m |
Revenue (TTM) | €2.23m |
57.8x
P/S Ratio-5.6x
P/E RatioIs 6OP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6OP income statement (TTM) | |
---|---|
Revenue | €2.23m |
Cost of Revenue | €0 |
Gross Profit | €2.23m |
Other Expenses | €25.23m |
Earnings | -€23.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.07 |
Gross Margin | 100.00% |
Net Profit Margin | -1,032.91% |
Debt/Equity Ratio | 182.4% |
How did 6OP perform over the long term?
See historical performance and comparison